Table 3.
Factors Associated With Linkage of Seroconversion Events
| Linked | Unlinked | P value | |
| Region | .60a | ||
| Africa | 24 (83%) | 5 (71%) | |
| Asia/America | 5 (17%) | 2 (29%) | |
| Index sex | .39a | ||
| Male | 10 (34%) | 4 (57%) | |
| Female | 19 (66%) | 3 (43%) | |
| Couple type | .033a | ||
| Male–male | 0 (0%) | 2 (29%) | |
| Other | 29 (100%) | 5 (71%) | |
| Index study arm | .018a | ||
| Early ART | 1 (3%) | 3 (43%) | |
| Deferred ART | 28 (97%) | 4 (57%) | |
| Index on ART at time of SC | .0076a | ||
| Yes | 2b (7%) | 4 (57%) | |
| No | 27 (93%) | 3d (43%) | |
| Index CD4 count at time of SC, median (IQR) | 352 (283–468) | 404 (301–540) | .41c |
| Years between enrollment and serconversion, median (IQR) | 1.0 (0.5–2.0) | 2.0 (0.7–2.7) | .25c |
| No. of sex partners in the 3 months before SCe | <.0001a | ||
| >1 | 0 (0%) | 4 (57%) | |
| 1 | 26 (90%) | 3 (43%) | |
| 0 | 2 (7%) | 0 (0%) | |
| Total | 29 | 7 |
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; SC, seroconversion; VL, viral load.
P value from Fisher exact test.
Two index participants in linked index-partner pairs were on ART at the time of that human immunodeficiency virus infection was documented in the partner (time of seroconversion). One of these participants was in the immediate ART arm of the HIV Prevention Trials Network (HPTN) 052 trial and initiated ART at the time of enrollment into the trial, approximately 3 months before the seroconversion event. The other index participant was in the delayed ART arm of the HPTN 052 trial and initiated ART approximately 4 weeks before the seroconversion event.
P value from Wilcoxon rank–sum test.
One participant was on ART due to pregnancy. She was considered not to be taking ART at the time of her partner’s seroconversion.
One participant in a linked seroconversion couple did not provide information about the number of sex partners in the 3 months before seroconversion.